CODX — Co-Diagnostics, Inc.

Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $0.6 million for the full year 2025, down from $3.9 million in 2024, primarily due to decreased grant revenue.
• Product Revenue: $0.4 million, a decline from $0.8 million in 2024, reflecting limited commercial activity.
• Operating Expenses: Increased to $50.6 million from $43.0 million, largely due to an $18.9 million noncash impairment charge related to R&D intangible assets.
• Net Loss: $46.9 million ($35.25 per share) compared to a loss of $37.6 million ($37.22 per share) in 2024. Excluding the impairment charge, the adjusted net loss would have been $28.0 million.
• Adjusted EBITDA: Loss of $28.0 million, improved from a loss of $33.5 million in 2024.
• Cash Position: Ended 2025 with $11.9 million in cash, down from $29.7 million at the end of 2024.

2. Strategic Updates and Business Highlights

• Regulatory Progress: Successfully relisted on NASDAQ after an appeal, focusing on execution and growth.
• CoSara Joint Venture: Expanded operations in India, now preparing to manufacture the PCR Pro instrument locally and has received CDSCO licensing for it. The addressable market in South Asia has increased to approximately $13 billion.
• CoMira Joint Venture: Progressing in Saudi Arabia, aiming to establish local manufacturing and distribution capabilities.
• Clinical Pipeline: Advancing tests for TB and HPV, with TB studies expected to start soon in India, leveraging the high disease burden.
• AI Integration: Expanding AI capabilities to enhance diagnostics and operational efficiency.

3. Forward Guidance and Outlook

• Commercialization Timeline: Anticipates commercialization of the TB test in India by Q3 2026.
• Clinical Submissions: Plans to submit for FDA approval for a multiplex respiratory test focusing on flu A, flu B, and RSV, with flexibility to add COVID-19 later if conditions allow.
• Funding Strategy: Actively exploring financing alternatives, including equity and strategic partnerships, while managing liquidity and costs.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant drop in total and product revenue year-over-year raises concerns about commercial traction.
• Operating Losses: Continued high operating losses, with expectations of further losses in the near term.
• Impairment Charge: The large noncash impairment charge indicates challenges in asset valuation and may reflect difficulties in achieving projected milestones.
• Regulatory Risks: Dependence on successful regulatory approvals for product commercialization poses inherent risks.

5. Notable Q&A Insights

• COVID-19 Testing: The decision to exclude COVID-19 from the multiplex test was based on sample availability rather than platform limitations. The company retains the flexibility to add COVID-19 testing later.
• Sample Requirements: For FDA studies, over 1,200 patient samples are expected to support the multiplex test submission.
• Expansion Strategy: The expansion into neighboring South Asian countries is aligned with the disease burden and aims to leverage existing infrastructure from the CoSara joint venture.

Overall, Co-Diagnostics is navigating a challenging financial landscape while pursuing strategic growth initiatives and regulatory milestones, with a focus on long-term commercialization and market expansion.